SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
GENB reported third quarter ended Sept. 30, 2026 results. The stock moved -6.8% on the print.
GENBearnings

Earnings reactions, page 3

Generate Biomedicines, Inc. (GENB) Q3 FY2026 earnings

November 12, 2026 · SharpeIQ Research Desk

Reported results

  • Revenue for the third quarter of 2026 was $4.2 million, compared with $9.6 million for the same period in 2025.
  • Research and development expenses were $82.3 million for the third quarter of 2026, compared with $62.2 million for the same period in 2025.
  • General and administrative expenses were $13.5 million for the third quarter of 2026, compared with $10.3 million for the same period in 2025.
  • Net loss was $87.7 million for the third quarter of 2026, compared with $60.0 million for the same period in 2025.
  • Cash, cash equivalents, and marketable securities were $404.2 million as of Sept. 30, 2026.

Price and volatility reaction

The stock moved -6.8% on the print. No front-expiry chain was on file, so there is no straddle expected move.

MeasureValueBasis
Close before release13.492026-11-11
Close after release12.572026-11-12
Realised move-6.8%close to close
Price and volatility reaction. Closes either side of the release. No front-expiry chain on file for a straddle expected move. SharpeIQ — listed option chain and price_history

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-12 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →